

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT



Atty. Ref. No.  
037003-0280721

Client Ref.  
1999-30-047001

Applicant: Paul Chinn

Appl. No.: 09/928,186

Filing Date: July 28, 2000

Examiner: Saunders

Group Art Unit: 1644

Date: July 7, 2004

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
QAG	AR 4,636,380	01/1987	Wong
	BR 4,816,567	03/1989	Cabilly
	CR 5,460,785	10/1995	Rhodes
	DR 5,541,287	07/1996	Yau

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
QAG	ER WO 92/07466	05/1992	PCT	Hellström				
	FR WO 88/04936	07/1988	PCT	Robinson				
	GR 0 274 394	07/1988	EP	Robinson				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)


QAG	HR	Adams RA, "Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma," <i>Cancer Research</i> , 1967, 27(1):2479-2482.
	IR	Adams RA, et al., "Direct implantation and transplantation of human acute lymphoblastic leukemia in hamsters, SB-2," 1968, <i>Cancer Research</i> , 1968, 28:1121-1125.
	JR	Chakrabarti MC et al., "Prevention of radiolysis of monoclonal antibody during labeling," <i>J. Nucl. Med.</i> , 1996, 37(8):1384-88.
	KR	DeNardo et al., "Yttrium-90/Indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer," <i>J. Nucl. Med.</i> , 1995, 36:97P.
	LR	Kozak RW, et al., "Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity," <i>Cancer Res.</i> , 1989, 49(10):2639-44.
	MR	Leland JK, et al., "Electrogenerated chemiluminescence: An oxidative-reduction type ECL reaction sequence using Tripropyl Amine," <i>Electrochem. Soc.</i> , 1990, 137, 3127.
	NR	Lewis et al., "A facile, water-soluble method for modification of proteins with DOTA," <i>Bioconj Chem.</i> , 1994, 5:565-76.
	OR	Lindmo T, et al., "Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess," <i>J Immunol Methods</i> , 1984, 72(1):77-89.
	PR	Liu AY, et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," <i>J. Immunol.</i> , 1987, 139/10:3521-26.
	QR	Mather SJ, et al., "Labeling monoclonal antibodies with yttrium-90," <i>Eur. J. Nucl. Med.</i> , 1989, 15:307-312.
	RR	Mirzadeh S., et al., "Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-Isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin," <i>Bioconj Chemistry</i> , 1990, 1(1):59.
	SR	Muller RJ, "Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay," <i>J Immunol Methods</i> , 1980, 34(4):345-52.
	TR	Parker BA, et al., "Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody," <i>Cancer Research</i> , 1990, 50:1022s-28s.
	UR	Pietersz GA, et al., "The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer," <i>Immunol. Cell Biol.</i> , 1987, 65:111-125.
	VR	Pizzarello, "Direct and indirect action. In Pizzarello and Witcofski, eds. <i>Basic Radiation Biology</i> , 2 <sup>nd</sup> ed. Philadelphia: Lea & Febger, 1975, pp. 20-29.
	WR	Robinson, RD et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> , 1991, 2:84-93.
	XR	Salako et al., "Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations," <i>J. Nucl. Med.</i> , 1998, 39:667-70.
	YR	Thomas et al., Gamma-interferon administration after 90Y radiolabeled antibody therapy: survival and hematopoietic toxicity studies," <i>Int. J. radiat. Oncol. Biol. Phys.</i> , 1995, 31:529-534.

Examiner: *Paul A. Saunders*

Date Considered: 8/5/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

0280721

1999-30-0470D1

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Paul Chinn

Appln. No.: 09/928,186

Filing Date: July 28, 2000

Date: May 28, 2004

Page 1 of 1

Examiner: Saunders

Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
DSJ	5,728,369	03/1998	Griffiths	424	1049	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
DSJ	AR	WO 94 11026 A	05/1994	PCT	Anderson				
DSJ	BR	0 529 645 A	03/1993	EP	Gansow				
	CR								
	DR								
	ER								
	FR								
	GR								
	HR								

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

IR	Brechbiel MW, et al., "Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies," <i>Inorganic Chemistry</i> , 1986, 25(16):2772-81.
JR	
KR	
LR	
MR	
NR	
OR	
PR	
QR	
RR	
SR	
TR	
UR	

Examiner

David A. Saunders

Date Considered:

8/4/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.